EUVIMEDEUVIMED entdecken
Crossref

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding

Darrick K Li, Yuan Pu, Yihang Liu, Kisung You, Michael G Nanna iD, Alyssa Harris, Joseph J Y Sung iD, Loren Laine iD, Dennis L Shung

Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1646-1657

DOI: 10.1111/apt.70615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 19.03.2026. Verfasst von Darrick K Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Gastrointestinal Hemorrhage, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiplatelet management in patients hospitalised for gastrointestinal bleeding (GIB) after percutaneous coronary intervention (PCI) requires balancing risks of rebleeding and clinical vascular events.

Aims

Evaluate the impact of antiplatelet resumption timing post‐endoscopy on rebleeding and clinical vascular events.

Methods

We performed a retrospective nationwide cohort study of patients hospitalised with post‐PCI GIB on dual antiplatelet therapy (DAPT) using the Vizient Clinical Database. Co‐primary outcomes were 30‐day rebleeding and 90‐day clinical vascular events after endoscopy. Multivariable Cox proportional hazards regression analysis was performed.

Results

Among 2979 patients with both antiplatelet agents held before endoscopy for GIB (46.0% upper; 34.8% lower), antiplatelet resumption > 7 days post‐endoscopy was associated with decreased 30‐day rebleeding (hazard ratio [HR] 0.66; 95% confidence interval [CI] [0.49–0.87]) and increased 90‐day clinical vascular events (HR 1.18 [1.02–1.36]) compared to restarting ≤ 1 day post‐endoscopy. Among 869 patients with one antiplatelet agent held before endoscopy for GIB (47.3% upper; 36.3% lower), resumption at > 7 days vs. ≤ 1 day had HR 0.69 (0.41–1.14) for rebleeding and HR 1.41 (0.97–2.04) for clinical vascular events. HRs for antiplatelet resumption > 3 days vs. ≤ 1 day post‐endoscopy were similar.

Conclusions

Antiplatelet resumption > 7 days after endoscopy in patients hospitalised with post‐PCI GIB is associated with decreased 30‐day rebleeding but increased 90‐day clinical vascular events compared with resumption ≤ 1 day post‐endoscopy. Similar tradeoffs were noted with antiplatelet resumption > 3 days post‐endoscopy. To optimise competing risks of rebleeding versus clinical vascular events, antiplatelet therapy should be resumed no later than 7 days post‐endoscopy, and preferably within 3–4 days.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsGastrointestinal HemorrhagePercutaneous Coronary InterventionHumansFemaleRetrospective StudiesMaleAgedTime FactorsMiddle AgedRecurrenceProportional Hazards ModelsTreatment Outcome

Stichwörter der Autor:innen

antiplateletclinical vascular eventsgastrointestinal bleedingpercutaneous coronary intervention

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Section of Digestive Diseases, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Department of Mathematics, Baruch College, New York, New York, USA.
  • Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Center for Advanced Analytics & Informatics, Vizient, Inc., Irving, Texas, USA.
  • VA Connecticut Healthcare System, West Haven, Connecticut, USA.

ORCID-Profile: Michael G Nanna, Joseph J Y Sung, Loren Laine

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Li, D. K., Pu, Y., Liu, Y., You, K., Nanna, M. G., Harris, A., Sung, J. J. Y., Laine, L., & Shung, D. L. (2026). Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding. Alimentary Pharmacology & Therapeutics, 63(12), 1646-1657. https://doi.org/10.1111/apt.70615

Vancouver

Li DK, Pu Y, Liu Y, You K, Nanna MG, Harris A, et al. Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding. Alimentary Pharmacology & Therapeutics. 2026;63(12):1646-1657. doi:10.1111/apt.70615

BibTeX
@article{Li2026,
  author = {Li, Darrick K and Pu, Yuan and Liu, Yihang and You, Kisung and Nanna, Michael G and Harris, Alyssa and Sung, Joseph J Y and Laine, Loren and Shung, Dennis L},
  title = {Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {12},
  pages = {1646--1657},
  doi = {10.1111/apt.70615}
}
Kostenlos starten →